BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.